Bluejay Therapeutics Stock

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases.

Sign up today and learn more about Bluejay Therapeutics Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Bluejay Therapeutics Stock

Bluejay Therapeutics is a private biopharmaceutical company focused on the development of cures for infectious diseases. The company’s first target indication is chronic Hepatitis B, which remains a worldwide prevalent disease with urgent unmet medical need. Bluejay is advancing two innovative approaches with the potential for high rate of functional cure: best-in-class fully human IgG1 anti-HBs monoclonal antibodies and first-in-class HBsAg oral small molecule inhibitors. The company believes that by reducing hepatitis B surface antigen and restoring adaptive immunity a functional cure could be achieved for patients.

Funding History

August 2022$41.0M

Management

Chief Scientific Officer

Hassan Javanbakht

Board Member

William Rutter

Board Member

Alon Lazarus

VP, Development

Kevin Lin

Chief Medical Officer

Nancy Shulman

Board Member

Ting Jia

Founder, Chief Executive Officer & Chairman of the Board

Keting Chu

VP, Head of Chemistry

Jeff Zablocki

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo